KPP Advisory Services LLC Sells 38 Shares of Humana Inc. (NYSE:HUM)

KPP Advisory Services LLC decreased its holdings in shares of Humana Inc. (NYSE:HUM) by 5.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 695 shares of the insurance provider’s stock after selling 38 shares during the period. KPP Advisory Services LLC’s holdings in Humana were worth $220,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Creative Financial Designs Inc. ADV lifted its stake in Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock valued at $27,000 after buying an additional 61 shares during the period. CarsonAllaria Wealth Management Ltd. boosted its stake in Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock worth $28,000 after acquiring an additional 39 shares during the last quarter. Atwood & Palmer Inc. acquired a new position in Humana during the third quarter valued at approximately $29,000. Ashton Thomas Securities LLC acquired a new stake in Humana in the third quarter worth $31,000. Finally, Your Advocates Ltd. LLP boosted its position in shares of Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on HUM shares. TD Cowen increased their price target on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Royal Bank of Canada cut their price target on shares of Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Cantor Fitzgerald reissued a “neutral” rating and set a $395.00 price objective on shares of Humana in a research report on Tuesday, October 1st. Barclays boosted their price objective on shares of Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, KeyCorp began coverage on Humana in a report on Friday, October 11th. They set a “sector weight” rating for the company. Twenty analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Humana currently has an average rating of “Hold” and a consensus price target of $315.86.

Humana Price Performance

HUM stock opened at $275.67 on Friday. The stock has a market cap of $33.19 billion, a price-to-earnings ratio of 24.42, a P/E/G ratio of 2.17 and a beta of 0.52. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The company has a 50 day simple moving average of $281.36 and a 200 day simple moving average of $331.81. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $527.18.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The business had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. Research analysts anticipate that Humana Inc. will post 15.86 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be paid a $0.885 dividend. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $3.54 annualized dividend and a dividend yield of 1.28%. Humana’s dividend payout ratio is 31.36%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.